An electrophysiological research of anti-tumor drug targeting TMEM16A
Konferenz: BIBE 2019 - The Third International Conference on Biological Information and Biomedical Engineering
20.06.2019 - 22.06.2019 in Hangzhou, China
Tagungsband: BIBE 2019
Seiten: 4Sprache: EnglischTyp: PDF
Persönliche VDE-Mitglieder erhalten auf diesen Artikel 10% Rabatt
Autoren:
Guo, Shuai; Zhan, Yong; An, Hailong (State Key Laboratory of Reliability and Intelligence of Electrical Equipment, Hebei University of Technology, Tianjin, China & Key Laboratory of Electromagnetic Field and Electrical Apparatus Reliability of Hebei Province, Hebei University of Technology, Tianjin, China & Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin, China)
Chen, Yafei (Key Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Sciences, Hebei University of Technology, Tianjin, China)
Inhalt:
TMEM16A is an important chloride channel and it is highly expressed in many cancers. As the proliferation and migration of cancer cells can be significantly reduced through inhibiting TMEM16A, so that TMEM16A is considered as a novel anticancer drug target. In this study, propofol was confirmed as a potent TMEM16A inhibitor by whole-cell patch clamp electrophysiology experiments. Propofol can inhibit the whole-cell currents of TMEM16A in concentration-dependent manner, and it can inhibit the proliferation and migration of LA795 cells which is a lung adenocarcinoma cell with high expressed of TMEM16A. Therefore, propofol can be used as a new chemotherapy drug for the development of lung adenocarcinoma therapy.